{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:09:51Z","timestamp":1778875791640,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["R33 AI088585"],"award-info":[{"award-number":["R33 AI088585"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007924","name":"University of Louisville","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 HL127518"],"award-info":[{"award-number":["U01 HL127518"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33 AI088585"],"award-info":[{"award-number":["R33 AI088585"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jcmgh.2020.08.009","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T11:42:27Z","timestamp":1598528547000},"page":"185-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model"],"prefix":"10.1016","volume":"11","author":[{"given":"Matthew","family":"Dent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal","family":"Hamorsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaut","family":"Vausselin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Dubuisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinari","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7231-3004","authenticated-orcid":false,"given":"Nobuyuki","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2020.08.009_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.20032","article-title":"Structural biology of hepatitis C virus","volume":"39","author":"Penin","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib4","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged\u2264 30 years\u2014Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20132012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib5","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib8","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2015.10.005","article-title":"Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12 weeks","volume":"64","author":"Feld","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib14","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0168-8278(16)64003-5","article-title":"Treatment of hepatitis C virus in patients with advanced cirrhosis: always justified? Analysis of the Hepa-C Registry","volume":"64","author":"Fern\u00e1ndez-Carrillo","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12072-016-9744-3","article-title":"Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review","volume":"10","author":"Jothimani","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180719","article-title":"Rate of hepatitis C viral clearance by human livers in human patients: liver transplantation modeling primary infection and implications for studying entry inhibition","volume":"12","author":"Hughes","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(16)00120-1","article-title":"New perspectives for preventing hepatitis C virus liver graft infection","volume":"16","author":"Felmlee","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-016-9724-7","article-title":"Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals","volume":"10","author":"Colpitts","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jasms.2007.11.022","article-title":"Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans","volume":"19","author":"Iacob","year":"2008","journal-title":"J\u00a0Am Soc Mass Spectrom"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nsmb.3293","article-title":"Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy","volume":"23","author":"Walls","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib22","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1016\/S0021-9258(18)86956-3","article-title":"Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells","volume":"265","author":"Leonard","year":"1990","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/glycob\/cwy059","article-title":"Analysis of protein landscapes around N-glycosylation sites from the PDB repository for understanding the structural basis of N-glycoprotein processing and maturation","volume":"28","author":"Suga","year":"2018","journal-title":"Glycobiology"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib24","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2019.07.021","article-title":"Engineering of a lectibody targeting high-mannose-type glycans of the HIV envelope","volume":"27","author":"Hamorsky","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42826-019-0032-y","article-title":"Characterization and applications of chimeric mice with humanized livers for preclinical drug development","volume":"36","author":"Tateno","year":"2020","journal-title":"Lab Anim Res"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib26","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1128\/AAC.02588-12","article-title":"Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides","volume":"57","author":"Hamorsky","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib27","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins","volume":"79","author":"Goffard","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib28","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1128\/AAC.00633-11","article-title":"Griffithsin has antiviral activity against hepatitis C virus","volume":"55","author":"Meuleman","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib29","doi-asserted-by":"crossref","first-page":"25177","DOI":"10.1074\/jbc.M602431200","article-title":"Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans","volume":"281","author":"Helle","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1107\/S0907444912040498","article-title":"Structural insights into the specific anti-HIV property of actinohivin: structure of its complex with the \u03b1(1-2)mannobiose moiety of gp120","volume":"68","author":"Hoque","year":"2012","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib31","doi-asserted-by":"crossref","first-page":"e02309","DOI":"10.1128\/JVI.02309-16","article-title":"Computational prediction of the heterodimeric and higher-order structure of gpE1\/gpE2 envelope glycoproteins encoded by hepatitis C virus","volume":"91","author":"Freedman","year":"2017","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib32","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.cgh.2017.11.045","article-title":"Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States","volume":"16","author":"Cholankeril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/gut.51.2.248","article-title":"Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C","volume":"51","author":"Wali","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1021\/acsinfecdis.7b00091","article-title":"Entry inhibitors: a perspective for prevention of hepatitis C virus infection in organ transplantation","volume":"3","author":"Colpitts","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12916-017-0815-7","article-title":"Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals","volume":"15","author":"Baumert","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib36","series-title":"Addressing the challenges of hepatitis C virus resistance and treatment failure","author":"Colpitts","year":"2016"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3390\/ijms21062091","article-title":"Hepatitis C virus entry: an intriguingly complex and highly regulated process","volume":"21","author":"Colpitts","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib38","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1016\/S0168-8278(15)30171-9","article-title":"LP17: Novel approach for the prevention of recurrent hepatitis C in liver transplant recipients: preliminary results from ongoing phase III trial with civacir","volume":"62","author":"Terrault","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jvh.12632","article-title":"Prevention of allograft HCV recurrence with\u00a0peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: a proof-of-concept study","volume":"24","author":"Smith","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib40","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib41","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jmb.2013.02.025","article-title":"Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly\u00a0neutralizing antibodies","volume":"425","author":"Pantua","year":"2013","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrmicro1707","article-title":"Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy","volume":"5","author":"Balzarini","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/COH.0000000000000183","article-title":"Epidemiology of hepatitis C virus in HIV-infected patients","volume":"10","author":"Peters","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11904-018-0393-0","article-title":"Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C","volume":"15","author":"Schranz","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib45","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MNH.0000000000000456","article-title":"Expanding deceased donor kidney transplantation: medical risk, infectious risk, hepatitis C virus, and HIV","volume":"27","author":"Ruck","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib46","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/lt.25320","article-title":"Liver transplantation today: where we are now and where we are going","volume":"24","author":"Bodzin","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib47","first-page":"3858","article-title":"Growth of human hepatoma cell lines with differentiated functions in chemically defined medium","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib48","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/JVI.01190-09","article-title":"Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication","volume":"84","author":"Goueslain","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib50","doi-asserted-by":"crossref","first-page":"23865","DOI":"10.1074\/jbc.M110.213942","article-title":"Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry","volume":"286","author":"Maurin","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib51","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.0711044105","article-title":"Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization","volume":"105","author":"Scheel","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib52","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1086\/593021","article-title":"Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection","volume":"198","author":"Jensen","year":"2008","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs","volume":"49","author":"Gottwein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib54","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/JVI.78.6.2994-3002.2004","article-title":"Characterization of functional hepatitis C virus envelope glycoproteins","volume":"78","author":"De Beeck","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib55","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/jvi.68.10.6147-6160.1994","article-title":"Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses","volume":"68","author":"Dubuisson","year":"1994","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib57","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep.27603","article-title":"Prevention of hepatitis C virus infection and\u00a0spread in human liver chimeric mice by an anti-CD81 monoclonal antibody","volume":"61","author":"Ji","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2020.08.009_bib58","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0016-5085(99)70185-X","article-title":"Real-time detection system for quantification of hepatitis C virus genome","volume":"116","author":"Takeuchi","year":"1999","journal-title":"Gastroenterology"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X20301338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X20301338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:26:05Z","timestamp":1778873165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X20301338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"alternative-id":["S2352345X20301338"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2020.08.009","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.22.056754","asserted-by":"object"}]},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2020.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}